Dexcom (DXCM)
NASDAQ:DXCM
Want to see DXCM full AI Analyst Report?
DXCM Stock Chart & Stats
$63.98
$0.53(0.67%)
At close: 4:00 PM EST
$63.98
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $89.98
Previous CloseN/A
Volume488.69K
Average Volume (3M)6.42M
Market Cap
$28.08B
Enterprise Value$28.72B
Total Cash (Recent Filing)$2.42B
Total Debt (Recent Filing)$1.38B
Price to Earnings (P/E)30.0
Beta1.10
Next Earnings
Jul 23, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.40
Shares Outstanding385,873,000
10 Day Avg. Volume7,430,462
30 Day Avg. Volume6,415,412
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)9.43
Price to Sales (P/S)5.56
P/FCF Ratio24.04
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue5.96
Enterprise Value/Gross Profit9.64
Enterprise Value/Ebitda22.22
Forecast
1Y Price Target
$80.68Price Target Upside26.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)2.59
Revenue Forecast (FY)$5.23B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueDexcom’s core business is a durable consumables model: regularly replaced sensors and periodic transmitters create annuity-like demand from an installed base. That structural recurring revenue supports predictable top-line, higher lifetime customer value, and resilience versus one-time device sales.
Sustained Margin ExpansionMaterial margin improvement reflects scalable manufacturing, pricing power, and operating leverage as volumes and efficiencies grow. Higher and expanding gross and operating margins bolster free cash flow potential and fund R&D and commercial investments without diluting returns.
Strong Cash Generation & Balance SheetRobust operating and free cash flow combined with a solid cash buffer and reduced leverage improves financial flexibility. This supports reinvestment, M&A optionality, share repurchases, and weathering reimbursement timing, enhancing long-term strategic optionality and capital allocation.
Bears Say
Reimbursement And Tender DependenceDurable growth depends on broad payer coverage; uncertain CMS timing leaves a large U.S. segment inaccessible for now. International expansion also relies on country tenders, which are lumpy. Both reimbursement and tender dynamics create sustained visibility risk for adoption and revenue.
Input-cost And Ramp Pressure On MarginsExposure to commodity and logistics inputs can structurally compress gross margins if costs persist. Simultaneous investments and Ireland manufacturing ramp will elevate near-term operating spend, testing the durability of recent margin gains unless offset by productivity or pricing.
Market Moderation And CompetitionStructural competition and a potentially moderating U.S. CGM market increase the need to sustain new patient starts and product conversions. Slower organic adoption or stronger competitor moves would pressure revenue growth and require higher sales/marketing or product differentiation to maintain share.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $89.98 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $28.08B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 23, 2026 which is in 47 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Apr 30, 2026. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.466 by $0.094.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.61.
How many shares outstanding does Dexcom have?
Dexcom has 385,873,000 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.56 in its last earnings report, beating expectations of $0.466. Following the earnings report the stock price went up 3.023%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.68 (26.11% Upside)
$80.68 (26.11% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 421.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.20%
12-Months-Change
Fundamentals
Return on Equity
33.83%
Trailing 12-Months
Asset Growth
-1.75%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive view: strong revenue growth (15% reported, 12% organic), robust margin expansion (gross margin improvement of ~600 bps and large increases in operating income and EBITDA margins), record global new patient starts, solid cash generation (~$2.4B) and successful product and reimbursement catalysts (G7 15-day uptake, Prime Therapeutics coverage, international wins). Key risks and constraints—chiefly CMS timing uncertainty, a potential 50–100 basis point gross margin headwind from fuel/resin costs, reliance on tenders for international growth, and the need to sustain record new patient starts in the U.S.—temper but do not outweigh the positive operational and financial momentum communicated on the call.View all DXCM earnings summariesDXCM Revenue Breakdown
71.53% U.S.
28.47% International
DXCM Stock 12 Month Forecast
Average Price Target
$80.68
▲(26.11% Upside)
Technical Analysis
Ownership Overview
0.43% Insiders
25.16% Mutual Funds
18.14% Other Institutional Investors
24.16% Public Companies and Individual Investors